CAR-T-19-DNR/ CAR-T-19 clinical study

CAR-T-19-DNR/ CAR-T-19 in the treatment of cd19-positive relapsed/refractory diffuse large b-cell lymphoma: an open, parallel explore clinical study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024218

Enrollment

Unknown

Registered

2019-06-30

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large b-cell lymphoma

Interventions

1:CAR-T-19-DNR

2:CAR-T-19

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Understand and sign the informed consent form; 2) Aged 18 to 70 years old at the time of screening male and female; 3) Relapsed/refractory CD19 positive diffuse large B cell lymphoma confirmed by histopathology and/or cytology; 4) The ECOG score 0 or 1 or 2.

Exclusion criteria

Exclusion criteria: 1) Allergic to any of the ingredients in the cell products; 2) After organ transplantation; 3) Previous allogeneic hematopoietic stem cell transplantation; 4) CD20 positive patients have not received targeted therapy such as CD20 monoclonal antibody.

Design outcomes

Primary

Measure	Time frame
Addvert effect;	—

Countries

China

Contacts

Public ContactWang Zhao

Beijing Friendship Hospital, Capital Medical University

catenny@hotmail.com+86 010-63016616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026